Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Jan;59(1):45-50.
doi: 10.1016/S0377-1237(03)80107-7. Epub 2011 Jul 21.

Artifical Blood

Y K Goorha  1 , Prabal Deb  2 , T Chatterjee  3 , P S Dhot  4 , R S Prasad  5
Affiliations
Review

Artifical Blood

Y K Goorha et al. Med J Armed Forces India. 2003 Jan.

Abstract

Elimination of unwanted side-effects, especially transfusion-transmitted diseases (HIV and hepatitis) and leucocyte-mediated allosensitisation, is an important goal of modern transfusion medicine. The problems and high cost factor involved in collecting and storing human blood and the pending world-wide shortages are the other driving forces contributing towards the development of blood substitutes. Two major areas of research in this endeavour are haemoglobin-based oxygen carriers (HBOCs) and perfluorochemicals. Even though they do not qualify as perfect red blood cell substitutes, these 'oxygen carrying solutions' have many potential clinical and non clinical usages. These can reach tissues more easily than normal red cells and can deliver oxygen directly. These are not without adverse effects, and extensive clinical trials are being conducted to test their safety and efficacy. New understandings on the mode of action of these products will help to define their utility and application. Only after successful clinical trials can they be used for patient management, after approval by the FDA.

Keywords: Blood substitute; Haemoglobin solutions; Perfluorocarbons.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hemoglobin based red cell substitutes
See this image and copyright information in PMC

References

    1. Tsuchida E. Introduction: Overview and perspectives. In: Tsuchida E, editor. Artificial red cells. John Wiley & Sons Ltd.; Tokyo: 1995. pp. 1–20.
    1. Scatena R, Giardina B. Raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier. Expert Opin Biol Ther. 2001;1(1):121–127. - PubMed
    1. Rabiner SF, Helbert JR, Lopas H, Bayne S. Evaluation of stroma-free haemoglobin solution for use as a plasma expander. J Exp Med. 1967;129:1127–1142. - PMC - PubMed
    1. Hoffman SJ, Looker DL, Roehrich JM, Halbert TR, Kondo A. Expression of fully functional tetrameric human haemoglobin in Escherichia coli. Proc Nat Acad Sci. 1990;87:8521–8525. - PMC - PubMed
    1. Swanson ME, Martin MJ, O’Donnell JK. Production of functional human haemoglobin in transgenic swine. Technol. 1992;10:557–559. - PubMed

LinkOut - more resources